“…Indeed, we have demonstrated that orally supplemented aTCT protects against stroke-induced lesion in the brain of spontaneously hypertensive rats (Khanna et al, 2005b). As small animal studies are recognized to be of limited reliability to predict success for stroke therapeutics in clinical trials (Kidwell et al, 2001), we developed a minimally invasive preclinical canine model (Rink et al, 2008) to test the efficacy of a tocotrienolenriched (TE) supplement in a randomized, blind, placebo (PBO)-controlled setting. Angiography, enabled in our large animal setting, helped elucidate that prophylactic TE supplementation improves collateral blood flow to the stroke-affected territory during stroke.…”